Physician profile
Mark Paul Grohol
NPI 1447271473
$7,700.41
in general payments reported to CMS, 2019-2025
23 companies · $6,193 in 2025
The $6,193 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $62.14 · 2021: $128 · 2022: $133 · 2023: $336 · 2024: $572 · 2025: $6,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,600 · Food and Beverage: $1,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,600.00 |
| Food and Beverage | $1,500.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nordic Pharma, INC. | $5,600.00 | 2025 | Lacrifill |
| Alcon Vision LLC | $586.54 | 2019-2025 | Rocklatan, Precision7, Total30 |
| Abbvie INC. | $254.75 | 2022-2025 | |
| Rxsight INC | $222.61 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Biotissue Holdings INC. | $138.14 | 2024-2025 | |
| Allergan, INC. | $115.54 | 2019-2021 | |
| Astellas Pharma US INC | $91.45 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $88.79 | 2024-2025 | Eylea Hd |
| Plexus Optix, INC. | $68.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $68.69 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $62.65 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $60.79 | 2023-2025 | Infuse, Biotrue |
| Johnson & Johnson Vision Care, INC. | $57.13 | 2023-2025 | Acuvue |
| Alimera Sciences, INC. | $45.92 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $44.56 | 2023-2024 | Syfovre |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $41.70 | 2020-2021 | |
| Oyster Point Pharma, INC. | $39.85 | 2023-2024 | Tyrvaya |
| Dompe US, INC. | $29.76 | 2025 | Oxervate |
| Ocular Therapeutix, INC. | $21.58 | 2025 | Dextenza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Coopervision INC. | $18.99 | 2024 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $11.59 | 2021 | |
| Aerie Pharmaceuticals, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Grohol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.